NV
Novo Nordisk
NVO · NYSE
$44.57 -1.31% (-$0.59)
1M -4.26%
Market Cap 1.36T kr
P/E Ratio 11.65x
Div. Yield 3.78%
ROE 59.09%
Bulios Fair Price
$49.02
10.0% upside
Trenutna cena
$44.57
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica NVO trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Moderate
6/9Valuation
61 /100
Fair P/FCF 27.73x
P/S 4.12x
P/B 6.13x
Growth
75 /100
Growing Rev. growth 20.43%
FCF growth 23.26%
Book val. growth 32.46%
Profitability
96 /100
Strong Net margin 35.35%
Op. margin 43.13%
FCF margin 14.85%
Quality
92 /100
Excellent ROE 59.09%
ROA 19.57%
Asset turnover 0.55x
Debt
81 /100
Low Current ratio 0.87x
Int. coverage 30.76x
Net debt/EBITDA 0.53x
Stability
70 /100
Stable Rev. volatility 12.92%
EPS volatility 25.50%
Profitable years 6
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o NVO
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Maziar Mike Doustdar
Employees
68,794
Headquarters
Bagsvaerd
Prihajajoči dogodki
04 NOV.
Earnings
Upcoming earnings report